Grey Wolf Health（WOLF）株式概要グレイウルフ・アニマル・ヘルス社は、カナダで動物の健康とウェルネスを提供する会社である。 詳細WOLF ファンダメンタル分析スノーフレーク・スコア評価2/6将来の成長0/6過去の実績5/6財務の健全性2/6配当金0/6報酬当社が推定した公正価値より22.8%で取引されている 過去1年間で収益は192.9%増加しました リスク分析利払いは収益で十分にカバーされない 意味のある時価総額がありません ( CA$60M )すべてのリスクチェックを見るWOLF Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.Your Fair ValueCA$Current PriceCA$1.7544.6% 割高 内在価値ディスカウントGrowth estimate overAnnual revenue growth rate5 Yearstime period%/yrDecreaseIncreasePastFuture-2m37m2016201920222025202620282031Revenue CA$36.6mEarnings CA$1.8mAdvancedSet Fair ValueView all narrativesGrey Wolf Health Corp. 競合他社CareRxSymbol: TSX:CRRXMarket cap: CA$217.0mCLS Holdings USASymbol: CNSX:CLSHMarket cap: CA$5.9mSucroSymbol: TSXV:SUGRMarket cap: CA$216.6mHealthleadSymbol: SET:HLMarket cap: ฿1.4b価格と性能株価の高値、安値、推移の概要Grey Wolf Health過去の株価現在の株価CA$1.7552週高値CA$1.8052週安値CA$0.97ベータ0.451ヶ月の変化3.55%3ヶ月変化31.58%1年変化80.41%3年間の変化94.44%5年間の変化-16.00%IPOからの変化-30.00%最新ニュースReported Earnings • May 22First quarter 2026 earnings released: EPS: CA$0.004 (vs CA$0.001 in 1Q 2025)First quarter 2026 results: EPS: CA$0.004 (up from CA$0.001 in 1Q 2025). Revenue: CA$8.75m (up 11% from 1Q 2025). Net income: CA$145.3k (up 433% from 1Q 2025). Profit margin: 1.7% (up from 0.3% in 1Q 2025). The increase in margin was driven by higher revenue. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 114 percentage points per year, which is a significant difference in performance.Valuation Update With 7 Day Price Move • Apr 23Investor sentiment improves as stock rises 23%After last week's 23% share price gain to CA$1.75, the stock trades at a trailing P/E ratio of 36.1x. Average trailing P/E is 24x in the Consumer Retailing industry in Canada. Total returns to shareholders of 157% over the past three years.Reported Earnings • Apr 19Full year 2025 earnings released: EPS: CA$0.05 (vs CA$0.023 in FY 2024)Full year 2025 results: EPS: CA$0.05 (up from CA$0.023 in FY 2024). Revenue: CA$35.8m (up 33% from FY 2024). Net income: CA$1.66m (up 135% from FY 2024). Profit margin: 4.6% (up from 2.6% in FY 2024). The increase in margin was driven by higher revenue. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 109 percentage points per year, which is a significant difference in performance.お知らせ • Apr 15Grey Wolf Animal Health Corp., Annual General Meeting, Jun 24, 2026Grey Wolf Animal Health Corp., Annual General Meeting, Jun 24, 2026.Valuation Update With 7 Day Price Move • Feb 03Investor sentiment improves as stock rises 15%After last week's 15% share price gain to CA$1.50, the stock trades at a trailing P/E ratio of 62.1x. Average trailing P/E is 22x in the Consumer Retailing industry in Canada. Total returns to shareholders of 83% over the past three years.分析記事 • Jan 31Grey Wolf Animal Health Corp.'s (CVE:WOLF) Share Price Not Quite Adding UpGrey Wolf Animal Health Corp.'s ( CVE:WOLF ) price-to-earnings (or "P/E") ratio of 62.1x might make it look like a...最新情報をもっと見るRecent updatesReported Earnings • May 22First quarter 2026 earnings released: EPS: CA$0.004 (vs CA$0.001 in 1Q 2025)First quarter 2026 results: EPS: CA$0.004 (up from CA$0.001 in 1Q 2025). Revenue: CA$8.75m (up 11% from 1Q 2025). Net income: CA$145.3k (up 433% from 1Q 2025). Profit margin: 1.7% (up from 0.3% in 1Q 2025). The increase in margin was driven by higher revenue. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 114 percentage points per year, which is a significant difference in performance.Valuation Update With 7 Day Price Move • Apr 23Investor sentiment improves as stock rises 23%After last week's 23% share price gain to CA$1.75, the stock trades at a trailing P/E ratio of 36.1x. Average trailing P/E is 24x in the Consumer Retailing industry in Canada. Total returns to shareholders of 157% over the past three years.Reported Earnings • Apr 19Full year 2025 earnings released: EPS: CA$0.05 (vs CA$0.023 in FY 2024)Full year 2025 results: EPS: CA$0.05 (up from CA$0.023 in FY 2024). Revenue: CA$35.8m (up 33% from FY 2024). Net income: CA$1.66m (up 135% from FY 2024). Profit margin: 4.6% (up from 2.6% in FY 2024). The increase in margin was driven by higher revenue. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 109 percentage points per year, which is a significant difference in performance.お知らせ • Apr 15Grey Wolf Animal Health Corp., Annual General Meeting, Jun 24, 2026Grey Wolf Animal Health Corp., Annual General Meeting, Jun 24, 2026.Valuation Update With 7 Day Price Move • Feb 03Investor sentiment improves as stock rises 15%After last week's 15% share price gain to CA$1.50, the stock trades at a trailing P/E ratio of 62.1x. Average trailing P/E is 22x in the Consumer Retailing industry in Canada. Total returns to shareholders of 83% over the past three years.分析記事 • Jan 31Grey Wolf Animal Health Corp.'s (CVE:WOLF) Share Price Not Quite Adding UpGrey Wolf Animal Health Corp.'s ( CVE:WOLF ) price-to-earnings (or "P/E") ratio of 62.1x might make it look like a...Reported Earnings • Nov 23Third quarter 2025 earnings released: EPS: CA$0.02 (vs CA$0.016 in 3Q 2024)Third quarter 2025 results: EPS: CA$0.02 (up from CA$0.016 in 3Q 2024). Revenue: CA$9.34m (up 35% from 3Q 2024). Net income: CA$549.0k (up 9.3% from 3Q 2024). Profit margin: 5.9% (down from 7.3% in 3Q 2024). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has fallen by 18% per year but the company’s share price has increased by 13% per year, which means it is well ahead of earnings.分析記事 • Oct 24Grey Wolf Animal Health (CVE:WOLF) Has A Pretty Healthy Balance SheetDavid Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...分析記事 • Aug 30Grey Wolf Animal Health Corp.'s (CVE:WOLF) 25% Share Price Surge Not Quite Adding UpDespite an already strong run, Grey Wolf Animal Health Corp. ( CVE:WOLF ) shares have been powering on, with a gain of...Reported Earnings • Aug 25Second quarter 2025 earnings released: EPS: CA$0.02 (vs CA$0.019 in 2Q 2024)Second quarter 2025 results: EPS: CA$0.02 (up from CA$0.019 in 2Q 2024). Revenue: CA$9.52m (up 32% from 2Q 2024). Net income: CA$751.2k (up 30% from 2Q 2024). Profit margin: 7.9% (down from 8.0% in 2Q 2024). The decrease in margin was driven by higher expenses.分析記事 • Jul 17If EPS Growth Is Important To You, Grey Wolf Animal Health (CVE:WOLF) Presents An OpportunityFor beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to...分析記事 • Jun 14Grey Wolf Animal Health Corp.'s (CVE:WOLF) Price Is Out Of Tune With EarningsGrey Wolf Animal Health Corp.'s ( CVE:WOLF ) price-to-earnings (or "P/E") ratio of 62.1x might make it look like a...Valuation Update With 7 Day Price Move • Jun 13Investor sentiment improves as stock rises 16%After last week's 16% share price gain to CA$1.10, the stock trades at a trailing P/E ratio of 62.1x. Average trailing P/E is 23x in the Consumer Retailing industry in Canada. Total returns to shareholders of 77% over the past year.Reported Earnings • May 23First quarter 2025 earnings released: EPS: CA$0.001 (vs CA$0.004 in 1Q 2024)First quarter 2025 results: EPS: CA$0.001 (down from CA$0.004 in 1Q 2024). Revenue: CA$7.92m (up 31% from 1Q 2024). Net income: CA$27.2k (down 78% from 1Q 2024). Profit margin: 0.3% (down from 2.1% in 1Q 2024). The decrease in margin was driven by higher expenses.New Risk • Apr 22New major risk - Financial positionThe company's debt is not well covered by operating cash flow. Operating cash flow to total debt ratio: 6.5% This is considered a major risk. If the company's operating cash flows are too small relative to the size of their debt, it increases their balance sheet risk. The company has less cash from operations to cover its expenses from servicing large debt and it increases the risk of liquidity issues. It also extends the time it would take for the company to pay back the debt in full, meaning it may not be able to easily pay it all off in a distress scenario. Currently, the following risks have been identified for the company: Major Risk Debt is not well covered by operating cash flow (6.5% operating cash flow to total debt). Minor Risk Market cap is less than US$100m (CA$32.5m market cap, or US$23.5m).Reported Earnings • Apr 20Full year 2024 earnings released: EPS: CA$0.02 (vs CA$0.02 in FY 2023)Full year 2024 results: EPS: CA$0.02 (in line with FY 2023). Revenue: CA$26.8m (up 5.6% from FY 2023). Net income: CA$704.7k (up 16% from FY 2023). Profit margin: 2.6% (up from 2.4% in FY 2023). The increase in margin was driven by higher revenue.お知らせ • Apr 14Grey Wolf Animal Health Corp., Annual General Meeting, Jun 19, 2025Grey Wolf Animal Health Corp., Annual General Meeting, Jun 19, 2025.Valuation Update With 7 Day Price Move • Dec 05Investor sentiment improves as stock rises 20%After last week's 20% share price gain to CA$1.09, the stock trades at a trailing P/E ratio of 40.4x. Average trailing P/E is 22x in the Pharmaceuticals industry in Canada. Total loss to shareholders of 41% over the past three years.分析記事 • Dec 04Investors Still Aren't Entirely Convinced By Grey Wolf Animal Health Corp.'s (CVE:WOLF) Revenues Despite 26% Price JumpGrey Wolf Animal Health Corp. ( CVE:WOLF ) shareholders have had their patience rewarded with a 26% share price jump in...New Risk • Dec 03New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 10% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Minor Risks Profit margins are more than 30% lower than last year (3.5% net profit margin). Shareholders have been diluted in the past year (10% increase in shares outstanding). Market cap is less than US$100m (CA$34.9m market cap, or US$24.8m).Reported Earnings • Nov 22Third quarter 2024 earnings released: EPS: CA$0.02 (vs CA$0.009 in 3Q 2023)Third quarter 2024 results: EPS: CA$0.02 (up from CA$0.009 in 3Q 2023). Revenue: CA$6.90m (up 5.7% from 3Q 2023). Net income: CA$502.2k (up 78% from 3Q 2023). Profit margin: 7.3% (up from 4.3% in 3Q 2023). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 63% per year but the company’s share price has fallen by 22% per year, which means it is significantly lagging earnings.New Risk • Nov 12New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Canadian stocks, typically moving 13% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (13% average weekly change). Profit margins are more than 30% lower than last year (2.7% net profit margin). Market cap is less than US$100m (CA$26.4m market cap, or US$18.9m).お知らせ • Oct 30Grey Wolf Animal Health Announces Launch of SILEOGrey Wolf Animal Health Corp. announced the Canadian commercial launch of SILEO® (dexmedetomidine hydrochloride oromucosal gel) to veterinary clinics throughout Canada. SILEO builds on Grey Wolf's portfolio dedicated to behaviour and anxiety health in companion animals. Dogs that experience fear and anxiety in response to loud noise such as fireworks now have a new treatment option. SILEO is available from veterinarians by prescription and can be administered at home by pet owners to help calm dogs without sedation.分析記事 • Aug 23These 4 Measures Indicate That Grey Wolf Animal Health (CVE:WOLF) Is Using Debt Reasonably WellThe external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...Reported Earnings • Aug 22Second quarter 2024 earnings released: EPS: CA$0.02 (vs CA$0.006 in 2Q 2023)Second quarter 2024 results: EPS: CA$0.02 (up from CA$0.006 in 2Q 2023). Revenue: CA$7.20m (up 7.7% from 2Q 2023). Net income: CA$577.5k (up 188% from 2Q 2023). Profit margin: 8.0% (up from 3.0% in 2Q 2023). The increase in margin was driven by higher revenue.Buy Or Sell Opportunity • Aug 12Now 21% undervalued after recent price dropOver the last 90 days, the stock has fallen 15% to CA$0.61. The fair value is estimated to be CA$0.77, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 8.0% over the last year. Meanwhile, the company has become profitable.Reported Earnings • May 24First quarter 2024 earnings released: EPS: CA$0.004 (vs CA$0.013 in 1Q 2023)First quarter 2024 results: EPS: CA$0.004 (down from CA$0.013 in 1Q 2023). Revenue: CA$6.05m (flat on 1Q 2023). Net income: CA$126.1k (down 69% from 1Q 2023). Profit margin: 2.1% (down from 6.8% in 1Q 2023).Board Change • May 21High number of new and inexperienced directorsThere are 4 new directors who have joined the board in the last 3 years. The company's board is composed of: 4 new directors. No experienced directors. 1 highly experienced director. Independent Director Rob Harris is the most experienced director on the board, commencing their role in 2016. The company’s lack of experienced directors is considered a risk according to the Simply Wall St Risk Model.分析記事 • Apr 19It's Down 25% But Grey Wolf Animal Health Corp. (CVE:WOLF) Could Be Riskier Than It LooksGrey Wolf Animal Health Corp. ( CVE:WOLF ) shareholders won't be pleased to see that the share price has had a very...Reported Earnings • Apr 12Full year 2023 earnings released: EPS: CA$0.02 (vs CA$0.15 in FY 2022)Full year 2023 results: EPS: CA$0.02 (down from CA$0.15 in FY 2022). Revenue: CA$25.4m (up 12% from FY 2022). Net income: CA$609.6k (down 76% from FY 2022). Profit margin: 2.4% (down from 11% in FY 2022). The decrease in margin was driven by higher expenses.お知らせ • Apr 12Grey Wolf Animal Health Corp., Annual General Meeting, Jun 19, 2024Grey Wolf Animal Health Corp., Annual General Meeting, Jun 19, 2024.分析記事 • Jan 22Grey Wolf Animal Health Corp.'s (CVE:WOLF) Shares Not Telling The Full StoryYou may think that with a price-to-sales (or "P/S") ratio of 1x Grey Wolf Animal Health Corp. ( CVE:WOLF ) is a stock...Reported Earnings • Nov 24Third quarter 2023 earnings released: EPS: CA$0.01 (vs CA$0.078 loss in 3Q 2022)Third quarter 2023 results: EPS: CA$0.01 (up from CA$0.078 loss in 3Q 2022). Revenue: CA$6.53m (up 12% from 3Q 2022). Net income: CA$282.5k (up CA$1.43m from 3Q 2022). Profit margin: 4.3% (up from net loss in 3Q 2022). The move to profitability was primarily driven by higher revenue.お知らせ • Nov 02Murray Roach to Leave Grey Wolf Animal Health Corp. as Chief Commercial OfficerGrey Wolf Animal Health Corp. announced that effective October 31, 2023 Murray Roach, Chief Commercial Officer, has decided to leave Grey Wolf.Reported Earnings • Aug 29Second quarter 2023 earnings released: EPS: CA$0.01 (vs CA$0.075 loss in 2Q 2022)Second quarter 2023 results: EPS: CA$0.01 (up from CA$0.075 loss in 2Q 2022). Revenue: CA$6.68m (up 8.8% from 2Q 2022). Net income: CA$200.5k (up CA$1.30m from 2Q 2022). Profit margin: 3.0% (up from net loss in 2Q 2022). The move to profitability was primarily driven by lower expenses.Reported Earnings • Jun 01First quarter 2023 earnings released: EPS: CA$0.013 (vs CA$0.072 loss in 1Q 2022)First quarter 2023 results: EPS: CA$0.013 (up from CA$0.072 loss in 1Q 2022). Revenue: CA$6.04m (up 7.0% from 1Q 2022). Net income: CA$410.5k (up CA$1.47m from 1Q 2022). Profit margin: 6.8% (up from net loss in 1Q 2022). The move to profitability was primarily driven by lower expenses.Reported Earnings • Apr 26Full year 2022 earnings releasedFull year 2022 results: Revenue: CA$22.6m (up 73% from FY 2021). Net income: CA$2.54m (up CA$3.51m from FY 2021). Profit margin: 11% (up from net loss in FY 2021). The move to profitability was driven by higher revenue.Reported Earnings • Dec 03Third quarter 2022 earnings releasedThird quarter 2022 results: CA$1.30 loss per share. Net loss: CA$1.14m (flat on 3Q 2021).お知らせ • Nov 29Grey Wolf Animal Health Corp. Announces Board ChangesGrey Wolf Animal Health Corp. announced that on November 15, 2022, the company completed the previously announced qualifying transaction with Magen Ventures I Inc. In connection with the completion of the qualifying transaction, the Company is also announcing (i) the resignation of Jolyon Burton, and (ii) the appointment of Jill Angevine and Diane Bourassa to Grey Wolf's Board of Directors as independent directors. Ms. Angevine is a finance professional with more than 25 years of experience in the investment management industry including portfolio management, capital markets and equity research. She currently serves as President and CEO of Brownstone Asset Management, a private investment firm, and holds non-executive directorships at additional public companies in the energy and mining sectors. Ms. Angevine holds a Bachelor of Commerce degree from the University of Calgary and has earned the Chartered Public Accountant (CPA, CA), the Chartered Financial Analyst (CFA), and the Institute of Corporate Directors (ICD.D) designations. Ms. Bourassa is a visionary business leader with extensive operational and financial expertise. Throughout her 30-year career, Ms. Bourassa succeeded in developing highly competitive and performing teams. Determined to share her skills and boundless energy with other companies, she has been focused since January 2022 on strategic consulting, individual coaching, and business development services. Ms. Bourassa worked for 14 years in the Canadian subsidiary of Vetoquinol S.A. Her leadership as General Manager of Vetoquinol Canada from 2011 to 2021 propelled Vetoquinol into the top 5 animal health pharmaceutical companies in Canada. Ms. Bourassa was a member of the Board of Directors of the Canadian Animal Health Institute for a period of 10 years, where she held various positions, including Chair of the Board of Directors from 2015 to 2016. Ms. Bourassa started her career at Ernst & Young and holds a CPA, CA designation.Board Change • Nov 25No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 4 non-independent directors. Founder, Director & CVMO Ian Sandler was the last director to join the board, commencing their role in 2022. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.株主還元WOLFCA Consumer RetailingCA 市場7D-2.2%4.9%-1.0%1Y80.4%15.5%28.9%株主還元を見る業界別リターン: WOLF過去 1 年間で15.5 % の収益を上げたCanadian Consumer Retailing業界を上回りました。リターン対市場: WOLF過去 1 年間で28.9 % の収益を上げたCanadian市場を上回りました。価格変動Is WOLF's price volatile compared to industry and market?WOLF volatilityWOLF Average Weekly Movement9.1%Consumer Retailing Industry Average Movement4.2%Market Average Movement9.7%10% most volatile stocks in CA Market16.6%10% least volatile stocks in CA Market3.7%安定した株価: WOLF 、 Canadian市場と比較して、過去 3 か月間で大きな価格変動はありませんでした。時間の経過による変動: WOLFの 週次ボラティリティ ( 9% ) は過去 1 年間安定しています。会社概要設立従業員CEO（最高経営責任者ウェブサイトn/an/aAngela Cechettogreywolfah.comグレイウルフ・アニマル・ヘルス社は、カナダで動物の健康とウェルネスを提供する会社である。アニマルヘルス事業部とファーマシー事業部の2つのセグメントで事業を展開。同社は動物病院向けに医薬品、栄養補助食品、消耗品の販売、マーケティング、流通を行っている。セダジェクト、アタジェクト、チロタブなどの犬用医薬品や、メディカルチューブ、ビスコースネットドレッシング、伸縮包帯、シリコーンパンチングテープなどの創傷ケア製品、ペットシャツ、ペットブーツ、ヘッドカバー、レッグスリーブなどのメディカルペットシャツ防護服などを提供している。また、注射器、注射針、点滴カテーテルなどの消耗品、コンポージャ・プロ、バーティフレックス、ハイド・アンド・トリート、L-リジン・プロ、レナル・エッセンシャルズ・プロ、ヘパティクリア・プロなどの栄養補助食品、エンテロ・エイド＋Gi、ファイバー・ブースト＋Giなどの健康食品も提供している。グレイウルフ・アニマルヘルス社の本社はカナダのトロントにある。もっと見るGrey Wolf Health Corp. 基礎のまとめGrey Wolf Health の収益と売上を時価総額と比較するとどうか。WOLF 基礎統計学時価総額CA$60.36m収益（TTM）CA$1.77m売上高(TTM)CA$36.60m34.0xPER（株価収益率1.6xP/SレシオWOLF は割高か？公正価値と評価分析を参照収益と収入最新の決算報告書（TTM）に基づく主な収益性統計WOLF 損益計算書（TTM）収益CA$36.60m売上原価CA$16.97m売上総利益CA$19.63mその他の費用CA$17.85m収益CA$1.77m直近の収益報告Mar 31, 2026次回決算日該当なし一株当たり利益（EPS）0.051グロス・マージン53.63%純利益率4.85%有利子負債／自己資本比率79.4%WOLF の長期的なパフォーマンスは？過去の実績と比較を見るView Valuation企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/06/30 00:47終値2026/06/30 00:00収益2026/03/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレークこのレポートを生成するために使用した分析モデルの詳細は、当社の Github ページ でご覧いただけます。また、レポートの使い方に関する ガイド や YouTube の チュートリアル もご用意しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Grey Wolf Health Corp. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
Reported Earnings • May 22First quarter 2026 earnings released: EPS: CA$0.004 (vs CA$0.001 in 1Q 2025)First quarter 2026 results: EPS: CA$0.004 (up from CA$0.001 in 1Q 2025). Revenue: CA$8.75m (up 11% from 1Q 2025). Net income: CA$145.3k (up 433% from 1Q 2025). Profit margin: 1.7% (up from 0.3% in 1Q 2025). The increase in margin was driven by higher revenue. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 114 percentage points per year, which is a significant difference in performance.
Valuation Update With 7 Day Price Move • Apr 23Investor sentiment improves as stock rises 23%After last week's 23% share price gain to CA$1.75, the stock trades at a trailing P/E ratio of 36.1x. Average trailing P/E is 24x in the Consumer Retailing industry in Canada. Total returns to shareholders of 157% over the past three years.
Reported Earnings • Apr 19Full year 2025 earnings released: EPS: CA$0.05 (vs CA$0.023 in FY 2024)Full year 2025 results: EPS: CA$0.05 (up from CA$0.023 in FY 2024). Revenue: CA$35.8m (up 33% from FY 2024). Net income: CA$1.66m (up 135% from FY 2024). Profit margin: 4.6% (up from 2.6% in FY 2024). The increase in margin was driven by higher revenue. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 109 percentage points per year, which is a significant difference in performance.
お知らせ • Apr 15Grey Wolf Animal Health Corp., Annual General Meeting, Jun 24, 2026Grey Wolf Animal Health Corp., Annual General Meeting, Jun 24, 2026.
Valuation Update With 7 Day Price Move • Feb 03Investor sentiment improves as stock rises 15%After last week's 15% share price gain to CA$1.50, the stock trades at a trailing P/E ratio of 62.1x. Average trailing P/E is 22x in the Consumer Retailing industry in Canada. Total returns to shareholders of 83% over the past three years.
分析記事 • Jan 31Grey Wolf Animal Health Corp.'s (CVE:WOLF) Share Price Not Quite Adding UpGrey Wolf Animal Health Corp.'s ( CVE:WOLF ) price-to-earnings (or "P/E") ratio of 62.1x might make it look like a...
Reported Earnings • May 22First quarter 2026 earnings released: EPS: CA$0.004 (vs CA$0.001 in 1Q 2025)First quarter 2026 results: EPS: CA$0.004 (up from CA$0.001 in 1Q 2025). Revenue: CA$8.75m (up 11% from 1Q 2025). Net income: CA$145.3k (up 433% from 1Q 2025). Profit margin: 1.7% (up from 0.3% in 1Q 2025). The increase in margin was driven by higher revenue. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 114 percentage points per year, which is a significant difference in performance.
Valuation Update With 7 Day Price Move • Apr 23Investor sentiment improves as stock rises 23%After last week's 23% share price gain to CA$1.75, the stock trades at a trailing P/E ratio of 36.1x. Average trailing P/E is 24x in the Consumer Retailing industry in Canada. Total returns to shareholders of 157% over the past three years.
Reported Earnings • Apr 19Full year 2025 earnings released: EPS: CA$0.05 (vs CA$0.023 in FY 2024)Full year 2025 results: EPS: CA$0.05 (up from CA$0.023 in FY 2024). Revenue: CA$35.8m (up 33% from FY 2024). Net income: CA$1.66m (up 135% from FY 2024). Profit margin: 4.6% (up from 2.6% in FY 2024). The increase in margin was driven by higher revenue. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 109 percentage points per year, which is a significant difference in performance.
お知らせ • Apr 15Grey Wolf Animal Health Corp., Annual General Meeting, Jun 24, 2026Grey Wolf Animal Health Corp., Annual General Meeting, Jun 24, 2026.
Valuation Update With 7 Day Price Move • Feb 03Investor sentiment improves as stock rises 15%After last week's 15% share price gain to CA$1.50, the stock trades at a trailing P/E ratio of 62.1x. Average trailing P/E is 22x in the Consumer Retailing industry in Canada. Total returns to shareholders of 83% over the past three years.
分析記事 • Jan 31Grey Wolf Animal Health Corp.'s (CVE:WOLF) Share Price Not Quite Adding UpGrey Wolf Animal Health Corp.'s ( CVE:WOLF ) price-to-earnings (or "P/E") ratio of 62.1x might make it look like a...
Reported Earnings • Nov 23Third quarter 2025 earnings released: EPS: CA$0.02 (vs CA$0.016 in 3Q 2024)Third quarter 2025 results: EPS: CA$0.02 (up from CA$0.016 in 3Q 2024). Revenue: CA$9.34m (up 35% from 3Q 2024). Net income: CA$549.0k (up 9.3% from 3Q 2024). Profit margin: 5.9% (down from 7.3% in 3Q 2024). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has fallen by 18% per year but the company’s share price has increased by 13% per year, which means it is well ahead of earnings.
分析記事 • Oct 24Grey Wolf Animal Health (CVE:WOLF) Has A Pretty Healthy Balance SheetDavid Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...
分析記事 • Aug 30Grey Wolf Animal Health Corp.'s (CVE:WOLF) 25% Share Price Surge Not Quite Adding UpDespite an already strong run, Grey Wolf Animal Health Corp. ( CVE:WOLF ) shares have been powering on, with a gain of...
Reported Earnings • Aug 25Second quarter 2025 earnings released: EPS: CA$0.02 (vs CA$0.019 in 2Q 2024)Second quarter 2025 results: EPS: CA$0.02 (up from CA$0.019 in 2Q 2024). Revenue: CA$9.52m (up 32% from 2Q 2024). Net income: CA$751.2k (up 30% from 2Q 2024). Profit margin: 7.9% (down from 8.0% in 2Q 2024). The decrease in margin was driven by higher expenses.
分析記事 • Jul 17If EPS Growth Is Important To You, Grey Wolf Animal Health (CVE:WOLF) Presents An OpportunityFor beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to...
分析記事 • Jun 14Grey Wolf Animal Health Corp.'s (CVE:WOLF) Price Is Out Of Tune With EarningsGrey Wolf Animal Health Corp.'s ( CVE:WOLF ) price-to-earnings (or "P/E") ratio of 62.1x might make it look like a...
Valuation Update With 7 Day Price Move • Jun 13Investor sentiment improves as stock rises 16%After last week's 16% share price gain to CA$1.10, the stock trades at a trailing P/E ratio of 62.1x. Average trailing P/E is 23x in the Consumer Retailing industry in Canada. Total returns to shareholders of 77% over the past year.
Reported Earnings • May 23First quarter 2025 earnings released: EPS: CA$0.001 (vs CA$0.004 in 1Q 2024)First quarter 2025 results: EPS: CA$0.001 (down from CA$0.004 in 1Q 2024). Revenue: CA$7.92m (up 31% from 1Q 2024). Net income: CA$27.2k (down 78% from 1Q 2024). Profit margin: 0.3% (down from 2.1% in 1Q 2024). The decrease in margin was driven by higher expenses.
New Risk • Apr 22New major risk - Financial positionThe company's debt is not well covered by operating cash flow. Operating cash flow to total debt ratio: 6.5% This is considered a major risk. If the company's operating cash flows are too small relative to the size of their debt, it increases their balance sheet risk. The company has less cash from operations to cover its expenses from servicing large debt and it increases the risk of liquidity issues. It also extends the time it would take for the company to pay back the debt in full, meaning it may not be able to easily pay it all off in a distress scenario. Currently, the following risks have been identified for the company: Major Risk Debt is not well covered by operating cash flow (6.5% operating cash flow to total debt). Minor Risk Market cap is less than US$100m (CA$32.5m market cap, or US$23.5m).
Reported Earnings • Apr 20Full year 2024 earnings released: EPS: CA$0.02 (vs CA$0.02 in FY 2023)Full year 2024 results: EPS: CA$0.02 (in line with FY 2023). Revenue: CA$26.8m (up 5.6% from FY 2023). Net income: CA$704.7k (up 16% from FY 2023). Profit margin: 2.6% (up from 2.4% in FY 2023). The increase in margin was driven by higher revenue.
お知らせ • Apr 14Grey Wolf Animal Health Corp., Annual General Meeting, Jun 19, 2025Grey Wolf Animal Health Corp., Annual General Meeting, Jun 19, 2025.
Valuation Update With 7 Day Price Move • Dec 05Investor sentiment improves as stock rises 20%After last week's 20% share price gain to CA$1.09, the stock trades at a trailing P/E ratio of 40.4x. Average trailing P/E is 22x in the Pharmaceuticals industry in Canada. Total loss to shareholders of 41% over the past three years.
分析記事 • Dec 04Investors Still Aren't Entirely Convinced By Grey Wolf Animal Health Corp.'s (CVE:WOLF) Revenues Despite 26% Price JumpGrey Wolf Animal Health Corp. ( CVE:WOLF ) shareholders have had their patience rewarded with a 26% share price jump in...
New Risk • Dec 03New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 10% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Minor Risks Profit margins are more than 30% lower than last year (3.5% net profit margin). Shareholders have been diluted in the past year (10% increase in shares outstanding). Market cap is less than US$100m (CA$34.9m market cap, or US$24.8m).
Reported Earnings • Nov 22Third quarter 2024 earnings released: EPS: CA$0.02 (vs CA$0.009 in 3Q 2023)Third quarter 2024 results: EPS: CA$0.02 (up from CA$0.009 in 3Q 2023). Revenue: CA$6.90m (up 5.7% from 3Q 2023). Net income: CA$502.2k (up 78% from 3Q 2023). Profit margin: 7.3% (up from 4.3% in 3Q 2023). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 63% per year but the company’s share price has fallen by 22% per year, which means it is significantly lagging earnings.
New Risk • Nov 12New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Canadian stocks, typically moving 13% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (13% average weekly change). Profit margins are more than 30% lower than last year (2.7% net profit margin). Market cap is less than US$100m (CA$26.4m market cap, or US$18.9m).
お知らせ • Oct 30Grey Wolf Animal Health Announces Launch of SILEOGrey Wolf Animal Health Corp. announced the Canadian commercial launch of SILEO® (dexmedetomidine hydrochloride oromucosal gel) to veterinary clinics throughout Canada. SILEO builds on Grey Wolf's portfolio dedicated to behaviour and anxiety health in companion animals. Dogs that experience fear and anxiety in response to loud noise such as fireworks now have a new treatment option. SILEO is available from veterinarians by prescription and can be administered at home by pet owners to help calm dogs without sedation.
分析記事 • Aug 23These 4 Measures Indicate That Grey Wolf Animal Health (CVE:WOLF) Is Using Debt Reasonably WellThe external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...
Reported Earnings • Aug 22Second quarter 2024 earnings released: EPS: CA$0.02 (vs CA$0.006 in 2Q 2023)Second quarter 2024 results: EPS: CA$0.02 (up from CA$0.006 in 2Q 2023). Revenue: CA$7.20m (up 7.7% from 2Q 2023). Net income: CA$577.5k (up 188% from 2Q 2023). Profit margin: 8.0% (up from 3.0% in 2Q 2023). The increase in margin was driven by higher revenue.
Buy Or Sell Opportunity • Aug 12Now 21% undervalued after recent price dropOver the last 90 days, the stock has fallen 15% to CA$0.61. The fair value is estimated to be CA$0.77, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 8.0% over the last year. Meanwhile, the company has become profitable.
Reported Earnings • May 24First quarter 2024 earnings released: EPS: CA$0.004 (vs CA$0.013 in 1Q 2023)First quarter 2024 results: EPS: CA$0.004 (down from CA$0.013 in 1Q 2023). Revenue: CA$6.05m (flat on 1Q 2023). Net income: CA$126.1k (down 69% from 1Q 2023). Profit margin: 2.1% (down from 6.8% in 1Q 2023).
Board Change • May 21High number of new and inexperienced directorsThere are 4 new directors who have joined the board in the last 3 years. The company's board is composed of: 4 new directors. No experienced directors. 1 highly experienced director. Independent Director Rob Harris is the most experienced director on the board, commencing their role in 2016. The company’s lack of experienced directors is considered a risk according to the Simply Wall St Risk Model.
分析記事 • Apr 19It's Down 25% But Grey Wolf Animal Health Corp. (CVE:WOLF) Could Be Riskier Than It LooksGrey Wolf Animal Health Corp. ( CVE:WOLF ) shareholders won't be pleased to see that the share price has had a very...
Reported Earnings • Apr 12Full year 2023 earnings released: EPS: CA$0.02 (vs CA$0.15 in FY 2022)Full year 2023 results: EPS: CA$0.02 (down from CA$0.15 in FY 2022). Revenue: CA$25.4m (up 12% from FY 2022). Net income: CA$609.6k (down 76% from FY 2022). Profit margin: 2.4% (down from 11% in FY 2022). The decrease in margin was driven by higher expenses.
お知らせ • Apr 12Grey Wolf Animal Health Corp., Annual General Meeting, Jun 19, 2024Grey Wolf Animal Health Corp., Annual General Meeting, Jun 19, 2024.
分析記事 • Jan 22Grey Wolf Animal Health Corp.'s (CVE:WOLF) Shares Not Telling The Full StoryYou may think that with a price-to-sales (or "P/S") ratio of 1x Grey Wolf Animal Health Corp. ( CVE:WOLF ) is a stock...
Reported Earnings • Nov 24Third quarter 2023 earnings released: EPS: CA$0.01 (vs CA$0.078 loss in 3Q 2022)Third quarter 2023 results: EPS: CA$0.01 (up from CA$0.078 loss in 3Q 2022). Revenue: CA$6.53m (up 12% from 3Q 2022). Net income: CA$282.5k (up CA$1.43m from 3Q 2022). Profit margin: 4.3% (up from net loss in 3Q 2022). The move to profitability was primarily driven by higher revenue.
お知らせ • Nov 02Murray Roach to Leave Grey Wolf Animal Health Corp. as Chief Commercial OfficerGrey Wolf Animal Health Corp. announced that effective October 31, 2023 Murray Roach, Chief Commercial Officer, has decided to leave Grey Wolf.
Reported Earnings • Aug 29Second quarter 2023 earnings released: EPS: CA$0.01 (vs CA$0.075 loss in 2Q 2022)Second quarter 2023 results: EPS: CA$0.01 (up from CA$0.075 loss in 2Q 2022). Revenue: CA$6.68m (up 8.8% from 2Q 2022). Net income: CA$200.5k (up CA$1.30m from 2Q 2022). Profit margin: 3.0% (up from net loss in 2Q 2022). The move to profitability was primarily driven by lower expenses.
Reported Earnings • Jun 01First quarter 2023 earnings released: EPS: CA$0.013 (vs CA$0.072 loss in 1Q 2022)First quarter 2023 results: EPS: CA$0.013 (up from CA$0.072 loss in 1Q 2022). Revenue: CA$6.04m (up 7.0% from 1Q 2022). Net income: CA$410.5k (up CA$1.47m from 1Q 2022). Profit margin: 6.8% (up from net loss in 1Q 2022). The move to profitability was primarily driven by lower expenses.
Reported Earnings • Apr 26Full year 2022 earnings releasedFull year 2022 results: Revenue: CA$22.6m (up 73% from FY 2021). Net income: CA$2.54m (up CA$3.51m from FY 2021). Profit margin: 11% (up from net loss in FY 2021). The move to profitability was driven by higher revenue.
Reported Earnings • Dec 03Third quarter 2022 earnings releasedThird quarter 2022 results: CA$1.30 loss per share. Net loss: CA$1.14m (flat on 3Q 2021).
お知らせ • Nov 29Grey Wolf Animal Health Corp. Announces Board ChangesGrey Wolf Animal Health Corp. announced that on November 15, 2022, the company completed the previously announced qualifying transaction with Magen Ventures I Inc. In connection with the completion of the qualifying transaction, the Company is also announcing (i) the resignation of Jolyon Burton, and (ii) the appointment of Jill Angevine and Diane Bourassa to Grey Wolf's Board of Directors as independent directors. Ms. Angevine is a finance professional with more than 25 years of experience in the investment management industry including portfolio management, capital markets and equity research. She currently serves as President and CEO of Brownstone Asset Management, a private investment firm, and holds non-executive directorships at additional public companies in the energy and mining sectors. Ms. Angevine holds a Bachelor of Commerce degree from the University of Calgary and has earned the Chartered Public Accountant (CPA, CA), the Chartered Financial Analyst (CFA), and the Institute of Corporate Directors (ICD.D) designations. Ms. Bourassa is a visionary business leader with extensive operational and financial expertise. Throughout her 30-year career, Ms. Bourassa succeeded in developing highly competitive and performing teams. Determined to share her skills and boundless energy with other companies, she has been focused since January 2022 on strategic consulting, individual coaching, and business development services. Ms. Bourassa worked for 14 years in the Canadian subsidiary of Vetoquinol S.A. Her leadership as General Manager of Vetoquinol Canada from 2011 to 2021 propelled Vetoquinol into the top 5 animal health pharmaceutical companies in Canada. Ms. Bourassa was a member of the Board of Directors of the Canadian Animal Health Institute for a period of 10 years, where she held various positions, including Chair of the Board of Directors from 2015 to 2016. Ms. Bourassa started her career at Ernst & Young and holds a CPA, CA designation.
Board Change • Nov 25No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 4 non-independent directors. Founder, Director & CVMO Ian Sandler was the last director to join the board, commencing their role in 2022. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.
